American Journal of Roentgenology · 1999 · 160 citations · 6 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingDiagnostic RadiologyEndocrine OncologyAdrenal ImagingAdrenal Mass EvaluationAdrenal TumorsEndocrine ImagingPositron Emission TomographyTumor DetectionAdrenal Cortex ImagingAdrenal Imaging Differential DiagnosisAdrenal Tumor DiagnosisAdrenal Tumor StagingBenign Adrenal Lesion AssessmentMalignant Adrenal Lesion AssessmentPositron Emission Tomography DetectionWhole-body Pet Imaging
OBJECTIVE: The aim of this study was to differentiate benign from malignant adrenal tumors using positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in patients with unilateral adrenal masses originally detected by CT or MR imaging. CONCLUSION: PET imaging with FDG can metabolically characterize adrenal masses. Abnormally increased FDG uptake in adrenal malignancies allows one to differentiate these abnormalities from benign lesions. Whole-body PET can also reveal extraadrenal tumor sites in patients with malignant tumors, using a single imaging technique for accurate disease staging.
6
State-of-the-art MR imaging of the adrenal gland.
M J Lee, William W. Mayo-Smith, P F Hahn et al. · Radiographics · 1994 · 78 citations
Medicine, Endocrinology, Radiology +17
The role of radiolabeled somatostatin analogs in adrenal imaging
Simone Maurea, Secondo Lastoria, Corradina Caracò et al. · Nuclear Medicine and Biology · 1996 · 31 citations
Medicine, Endocrinology, Radiology +14